Meta-Analysis Comparing the Safety and Efficacy of Dual Versus Triple Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Meta-Analysis Comparing the Safety and Efficacy of Dual Versus Triple Antithrombotic Therapy in... In patients with atrial fibrillation undergoing percutaneous coronary intervention (PCI), the effectiveness and safety of dual compared with triple antithrombotic therapy are a matter of debate, especially when considering the prevention of end points at low incidence, such as myocardial infarction (MI), stent thrombosis, or mortality. This study-level meta-analysis included 4 controlled randomized trials and 6,036 patients with a clinical indication to chronic oral anticoagulation (OAC) after PCI, mainly for atrial fibrillation. Patients receiving dual therapy with a single antiplatelet agent, essentially a P2Y12 inhibitor, plus OAC were compared with those treated with triple therapy (aspirin, a P2Y12 inhibitor, and OAC). The incidence of the following outcomes was evaluated: Thrombolysis In Myocardial Infarction major and minor bleeding, MI, stent thrombosis, stroke, cardiovascular, and all-cause death. Occurrence of Thrombolysis In Myocardial Infarction major bleeding was significantly lower in patients treated with dual therapy: 1.97% versus 3.53% in those on triple therapy (odds ratios 0.55, 95% confidence interval 0.39 to 0.78, p = 0.0007); rates of minor bleeding were also decreased in the former (57% relative reduction). With dual therapy, there was not a statistically significant difference in all-cause and cardiovascular mortality (3.81% vs 4.01%, p = 0.37 and 1.62% vs 2.02%, p = 0.42, respectively). Incidence of MI (3.25% vs 2.78%, p = 0.61), definite stent thrombosis (0.92% vs 0.66%, p = 0.46), and stroke (1.28% vs 1.32%, p = 0.85) was similar in the 2 treatment strategies. In patients with long-term indication to OAC after PCI, compared with triple therapy, dual antithrombotic therapy reduces bleeding, without an excess in thromboembolic and ischemic cardiac events. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The American Journal of Cardiology Elsevier

Meta-Analysis Comparing the Safety and Efficacy of Dual Versus Triple Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Loading next page...
 
/lp/elsevier/meta-analysis-comparing-the-safety-and-efficacy-of-dual-versus-triple-8wxwUitbhO
Publisher
Elsevier
Copyright
Copyright © 2017 Elsevier Inc.
ISSN
0002-9149
D.O.I.
10.1016/j.amjcard.2017.12.014
Publisher site
See Article on Publisher Site

Abstract

In patients with atrial fibrillation undergoing percutaneous coronary intervention (PCI), the effectiveness and safety of dual compared with triple antithrombotic therapy are a matter of debate, especially when considering the prevention of end points at low incidence, such as myocardial infarction (MI), stent thrombosis, or mortality. This study-level meta-analysis included 4 controlled randomized trials and 6,036 patients with a clinical indication to chronic oral anticoagulation (OAC) after PCI, mainly for atrial fibrillation. Patients receiving dual therapy with a single antiplatelet agent, essentially a P2Y12 inhibitor, plus OAC were compared with those treated with triple therapy (aspirin, a P2Y12 inhibitor, and OAC). The incidence of the following outcomes was evaluated: Thrombolysis In Myocardial Infarction major and minor bleeding, MI, stent thrombosis, stroke, cardiovascular, and all-cause death. Occurrence of Thrombolysis In Myocardial Infarction major bleeding was significantly lower in patients treated with dual therapy: 1.97% versus 3.53% in those on triple therapy (odds ratios 0.55, 95% confidence interval 0.39 to 0.78, p = 0.0007); rates of minor bleeding were also decreased in the former (57% relative reduction). With dual therapy, there was not a statistically significant difference in all-cause and cardiovascular mortality (3.81% vs 4.01%, p = 0.37 and 1.62% vs 2.02%, p = 0.42, respectively). Incidence of MI (3.25% vs 2.78%, p = 0.61), definite stent thrombosis (0.92% vs 0.66%, p = 0.46), and stroke (1.28% vs 1.32%, p = 0.85) was similar in the 2 treatment strategies. In patients with long-term indication to OAC after PCI, compared with triple therapy, dual antithrombotic therapy reduces bleeding, without an excess in thromboembolic and ischemic cardiac events.

Journal

The American Journal of CardiologyElsevier

Published: Mar 15, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from Google Scholar, PubMed
Create lists to organize your research
Export lists, citations
Access to DeepDyve database
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off